Not for distribution to U.S. Newswire Services or for dissemination in theUnited States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.
TORONTO, May 18, 2020 (GLOBE NEWSWIRE) -- Buzz Capital Inc. (TSXV: BUZ.P) ("Buzz Capital" or the "Corporation"), a capital pool company listed on the TSX Venture Exchange (the "Exchange"), is pleased to announce that it has signed a letter of intent datedMay 8, 2020 (the "Letter of Intent") with Novamind Ventures Inc., an Ontario corporation, ("Novamind) to complete a business combination by way of a transaction that will constitute a reverse takeover of Buzz Capital by Novamind. The proposed transaction is intended to constitute an arms length qualifying transaction (the "Qualifying Transaction") for Buzz Capital, as defined in Policy 2.4 of the Exchange. Upon completion of the Qualifying Transaction and the Financing (as defined and described below), it is expected that Buzz Capital (following the Qualifying Transaction, the Resulting Issuer) will be a Tier 2 Industrial Issuer, subject to Exchange approval.
Description of Novamind
Novamind invests in the infrastructure that drives the worlds leading psychedelic clinics and retreats. Novamind was founded in May 2019 in Toronto, Canada.
Ongoing clinical trials approved by the U.S. Food and Drug Administration (FDA) are currently evaluating the safety and efficacy of MDMA-assisted psychotherapy (to treat PTSD) and psilocybin-assisted psychotherapy (to treat depression), and if approved, will require specialized infrastructure to facilitate patient treatment. Novamind seeks to accelerate research and innovation in psychedelic medicine by investing in the people, science and technology required for a regulated psychedelics industry.
Until such time that the FDA approves new psychedelic medicines, Novamind invests and operates exclusively in those jurisdictions with established legal regulations for the use of psychedelics. With this as a prerequisite, Novamind was an early mover in 2019 and made two strategic investments in industry-leading psychedelic retreats and clinics:
Novaminds investment in Synthesis and its acquisition (pending) of Cedar Psychiatry provides Novamind with access to proprietary resources including psychedelic-assisted psychotherapy protocols, industry-leading data, patient screening tools, leading facilitators and scientific advisors. Utilizing these best practices and partnering with leading practitioners in the psychedelic space, Novamind is building a network of clinics and retreats offering people access to safe, legal psychedelic experiences while advancing research for psychedelic medicine.
Additional information on Novamind will be provided in the filing statement to be filed pursuant to the Qualifying Transaction.
The Qualifying Transaction
The Letter of Intent contemplates that the Qualifying Transaction will be undertaken by way of a three-corner amalgamation, pursuant to which Novamind will amalgamate (the "Amalgamation") with a newly formed subsidiary of Buzz Capital and, as such, approval of the Novamind shareholders (Novamind Shareholders) will be required. Upon completion of the Amalgamation, the corporation formed by the amalgamation of Novamind and the newly-formed subsidiary of Buzz Capital will be a wholly-owned subsidiary of Buzz Capital.
Prior to the Amalgamation, Buzz Capital will effect a consolidation (the Buzz Consolidation) and Novamind will similarly effect a consolidation (the Novamind Consolidation; together with the Buzz Consolidation, the Consolidations) of, respectively, the issued and outstanding common shares of Buzz Capital (the Buzz Shares) and Novamind (the Novamind Shares). Under the Buzz Consolidation, the Buzz Shares will be consolidated on a basis that results in the holders of Buzz Shares (Buzz Shareholders) holding post-Buzz Consolidation Buzz Shares (Buzz Consolidated Shares) having a value of $1,700,000, provided that Buzz Capital has net cash of minimum $500,000 at closing. Assuming a net cash position of a minimum of $500,000, this would result in the Buzz Shares being consolidated on a 1:1.9788 basis, resulting in approximately 4,250,000 Buzz Consolidated Shares being outstanding. Under the Novamind Consolidation, the outstanding Novamind Shares will be consolidated on a 1:4 basis, resulting in Novamind Shareholders holding approximately 19,018,750 post-Novamind Consolidation Novamind Shares (Novamind Consolidated Shares). The number and exercise prices of the outstanding convertible securities of Buzz Capital (Buzz Convertible Securities) and Novamind (Novamind Convertible Securities; together with the Buzz Convertible Securities, the Convertible Securities) will be adjusted in accordance with their terms as a result of, respectively, the Buzz Consolidation and Novamind Consolidation.
Following the Consolidations and pursuant to the Amalgamation, the holders of Novamind Consolidated Shares immediately prior to the completion of the Amalgamation will each receive, for every one (1) Novamind Consolidated Share held immediately prior to the completion of the Amalgamation, one (1) Buzz Consolidated Share (the Exchange Ratio). Outstanding Novamind Convertible Securities will either automatically adjust in accordance with the terms thereof such that following the completion of the Amalgamation, the holders thereof shall acquire Buzz Consolidated Shares in lieu of Novamind Consolidated Shares or will be replaced with equivalent convertible securities of Buzz entitling the holders thereof to acquire Buzz Consolidated Shares in lieu of Novamind Consolidated Shares, and otherwise bearing the same terms as the Novamind Convertible Securities which they replace.
Completion of the Qualifying Transaction is subject to the satisfaction of a number of conditions, including, but not limited to:
Selected Financial Information of Novamind
The following tables sets out unaudited historical financial information of Novamind for the period commencing on its date of incorporation, May 22, 2019 and ending April 30, 2020.
Novamind Financing
In connection with the Qualifying Transaction and prior to the Novamind Consolidation, Novamind is undertaking a non-brokered private placement (the Financing) of Novamind Shares at a price of $0.10 per share for minimum gross proceeds of $2,500,000. Novamind engaged First Republic Capital Corporation (First Republic) as its exclusive lead finder in connection with the Financing. As compensation, First Republic will be paid a cash commission equal to 7% of the aggregate gross proceeds of the Financing and compensation warrants (Compensation Warrants) equal to 7% of the number of Novamind Shares issued under the Financing. Each Compensation Warrant entitles the holder to acquire a Novamind Share at an exercise price of $0.10 for a period of 24 months following the closing date of the Financing. The Novamind Consolidation will result in the number of Novamind Shares and Compensation Warrants issued in the Financing being divided by four, and the effective offering price under the Financing and the exercise price of the Compensation Warrants being adjusted to $0.40 per share. Novamind has closed a first tranche of the Financing for gross proceeds of $1,607,500.
Pro Forma Capitalization
The table below demonstrates the anticipated non-diluted capitalization of the Resulting Issuer post Qualifying Transaction and Financing, assuming completion of the minimum Financing, and lists the number of common shares of the Resulting Issuer (Resulting Issuer Shares) anticipated to be held by the Buzz Shareholders, Novamind Shareholders and investors in the Financing.
Note:
It is anticipated that proceeds from the Financing will be used for acquisitions and for general working capital.
Board of Directors, Officers and other Insiders
Upon completion of the Qualifying Transaction, it is anticipated that the board of directors and officers of the Resulting Issuer will be comprised of the individuals listed below. In addition, the parties anticipate that Novamind will nominate the Chief Financial Officer and Corporate Secretary of the Resulting Issuer. The identities and biographies of these individuals will be disclosed in a subsequent press release or filing statement prepared in connection with the Qualifying Transaction. To the knowledge of Novamind and Buzz Capital, no person will beneficially own, directly or indirectly, or exercise control or direction over, more than 10% of the Resulting Issuer.
Chuck Rifici (Director), Ottawa, Ontario
Chuck is a pioneer of the North American cannabis industry, having created and managed opportunities which have had an incredible and widespread impact on the Canadian cannabis landscape. The founder of Canopy Growth (FKA Tweed Marijuana), Chuck is Chairman of Auxly Cannabis Group, Chairman at Feather Company and is a chartered professional accountant (CPA). He obtained his MBA from Queens University and holds a BASc in Computer Engineering from the University of Ottawa.
Yaron Conforti (Chief Executive Officer and Director), Toronto, Ontario
Yaron Conforti is the founder and principal of Emmcap Corp., an investor in venture-stage companies. He previously served in senior investment banking roles at Desjardins Securities and Sandfire Securities and in CEO, CFO and corporate director roles for private and public companies.
Jesse Kaplan, CFA (Director), Toronto, Ontario
Jesse Kaplan has been a partner with Plaza Capital Limited since 2015. His career has focused on advising and investing in early stage growth companies. This has included extensive work helping companies through the process of going public in both Canada and the United States. Jesse was previously a senior analyst at Harborview Advisors LLC, a New York based investment firm and Palladium Capital Advisors, LLC, a NASD member investment bank. Currently, he is a board member of Abacus Health Products (CSE:ABCS) among other successful companies.
Sruli Weinreb (Director), Toronto, Ontario
Sruli Weinreb is the founder and managing partner of Plaza Capital Limited. Plaza Capital supports many North American early stage growth companies with strategic debt placements and equity investments. He is also the chief executive officer of Lake Central Air Services Inc., the worlds leading modification and integration partner for the airborne geophysical survey industry. Before founding Plaza Capital in 2013, Sruli was the chief executive officer of eMobile Inc., a telecom arbitrage company with a specialization in international roaming which he co-founded in 2008.
Sponsorship
Sponsorship of a qualifying transaction of a capital pool company is required by the Exchange unless exempt in accordance with Exchange policies. Buzz Capital is currently reviewing the requirements for sponsorship and may apply for an exemption from the sponsorship requirements pursuant to the policies of the Exchange; however, there is no assurance that Buzz Capital will ultimately obtain this exemption. Buzz Capital intends to include any additional information regarding sponsorship in a subsequent press release.
Further Information
The Buzz Shares are currently halted from trading on the Exchange and will remain halted until such time as determined by the Exchange, which, depending on the policies of the Exchange, may or may not occur until the completion of the Qualifying Transaction.
All information contained in this news release with respect to Novamind and Buzz Capital was supplied by the parties respectively, for inclusion herein, and each party and its directors and officers have relied on the other party for any information concerning the other party.
Completion of the transaction is subject to a number of conditions, including, but not limited to, Exchange acceptance and if applicable pursuant to Exchange requirements, majority of the minority shareholder approval.
Where applicable, the transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all.
Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the transaction, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.
The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statements
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the intention of the parties to enter into the Definitive Agreement, the completion of the Financing and Amalgamation, listing as an Industrial Issuer, and the use of proceeds from the Financing. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Corporation. The material factors and assumptions include the parties to the Definitive Agreement being able to obtain the necessary director, shareholder and regulatory approvals; Exchange policies not changing; and completion of satisfactory due diligence. Risk factors that could cause actual results or outcomes to differ materially from the results expressed or implied by forward-looking information include, among other things: conditions imposed by the Exchange, the failure to obtain the required directors' and shareholders' approval to the Qualifying Transaction; changes in tax laws, general economic and business conditions; and changes in the regulatory regulation. The Corporation cautions the reader that the above list of risk factors is not exhaustive. The forward-looking information contained in this release is made as of the date hereof and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in theUnited States. The securities have not been and will not be registered under theUnited StatesSecurities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within theUnited Statesor to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
SOURCE: Buzz Capital Inc.
For further information:
Buzz Capital Inc. Chuck RificiCEO, CFO and Director
Tel: (613) 239-0531
Novamind Ventures Inc. Yaron ConfortiCEO and Director
Tel: (647) 953-9512
Website: http://www.novamind.ca
Link:
Novamind and Buzz Capital Announce Qualifying Transaction TSX Venture Exchange:BUZ-P - GlobeNewswire
- 8 Mystical Herbs and Legal Psychedelics For Lucid Dreaming [Last Updated On: December 8th, 2016] [Originally Added On: December 8th, 2016]
- Psychedelics: LSD, Mushrooms, Salvia | Facts | Drug Policy ... [Last Updated On: December 10th, 2016] [Originally Added On: December 10th, 2016]
- FS Book Company - Marijuana Books [Last Updated On: December 12th, 2016] [Originally Added On: December 12th, 2016]
- Psychedelic - PsychonautWiki [Last Updated On: December 27th, 2016] [Originally Added On: December 27th, 2016]
- From Alzheimer's To Psychedelics, 2016 Was A Good Year For ... [Last Updated On: January 3rd, 2017] [Originally Added On: January 3rd, 2017]
- LSD - Psychedelic Effects - The Good Drugs Guide [Last Updated On: January 5th, 2017] [Originally Added On: January 5th, 2017]
- THC - Psychedelics [Last Updated On: January 29th, 2017] [Originally Added On: January 29th, 2017]
- Psychedelics | Pharmacological Reviews [Last Updated On: January 30th, 2017] [Originally Added On: January 30th, 2017]
- Dorian Yates reveals all on steroids, body dysmorphia, psychedelics, cannabis and yoga - Express.co.uk [Last Updated On: February 7th, 2017] [Originally Added On: February 7th, 2017]
- Psychedelic drug therapy including magic mushrooms, LSD and ... - CBS News [Last Updated On: February 7th, 2017] [Originally Added On: February 7th, 2017]
- Psychedelics Being Tested For Use In Treating Various Conditions - CBS Local [Last Updated On: February 8th, 2017] [Originally Added On: February 8th, 2017]
- The psychedelic renaissance - Boulder Weekly [Last Updated On: February 9th, 2017] [Originally Added On: February 9th, 2017]
- Buy psychedelics online : Chinglabs.com [Last Updated On: February 12th, 2017] [Originally Added On: February 12th, 2017]
- Psychedelic drugs like magic mushrooms and LSD have key ... - Yahoo Finance [Last Updated On: February 13th, 2017] [Originally Added On: February 13th, 2017]
- Psychedelics a Viable Therapeutic Option for Depression - Psychiatry Advisor [Last Updated On: February 14th, 2017] [Originally Added On: February 14th, 2017]
- Is Silicon Valley Onto Something With Its LSD Microdosing? - Newsweek [Last Updated On: February 15th, 2017] [Originally Added On: February 15th, 2017]
- News Releases - Noozhawk [Last Updated On: February 16th, 2017] [Originally Added On: February 16th, 2017]
- A Revolution in the Science of Psychedelics is Happening in Boulder - 303 Magazine [Last Updated On: February 16th, 2017] [Originally Added On: February 16th, 2017]
- When Reality Is More Intense Than Psychedelics: Strand Of Oaks ... - NPR [Last Updated On: February 17th, 2017] [Originally Added On: February 17th, 2017]
- Psychedelics Help Reduce Opioid Addiction, According to New Study - AlterNet [Last Updated On: February 22nd, 2017] [Originally Added On: February 22nd, 2017]
- Psychedelics May Help Reduce Opioid Addiction, According To ... - Huffington Post [Last Updated On: February 23rd, 2017] [Originally Added On: February 23rd, 2017]
- Psychedelics Help Reduce Opioid Addiction, According to New Study - eNews Park Forest [Last Updated On: February 24th, 2017] [Originally Added On: February 24th, 2017]
- Psychedelics Could Play A Role In Tackling The Opioid Epidemic - Huffington Post [Last Updated On: February 24th, 2017] [Originally Added On: February 24th, 2017]
- Meet The People's Champion of Psychedelic Drugs - Narratively [Last Updated On: February 27th, 2017] [Originally Added On: February 27th, 2017]
- How psychedelics like psilocybin and LSD actually change the way ... - Yahoo Finance [Last Updated On: February 27th, 2017] [Originally Added On: February 27th, 2017]
- First U. student group on studying psychedelics holds open house - The Daily Princetonian [Last Updated On: February 27th, 2017] [Originally Added On: February 27th, 2017]
- How psychedelics like psilocybin and LSD actually change the way people see the world - Businessinsider India [Last Updated On: February 28th, 2017] [Originally Added On: February 28th, 2017]
- Psychedelics Help Reduce Opioid Addiction, According to New ... [Last Updated On: February 28th, 2017] [Originally Added On: February 28th, 2017]
- WATCH: A Public Policy Expert Explains How to Safely Deregulate LSD and Other Psychedelics - AlterNet [Last Updated On: March 7th, 2017] [Originally Added On: March 7th, 2017]
- Quotes About Psychedelics (48 quotes) [Last Updated On: March 7th, 2017] [Originally Added On: March 7th, 2017]
- Inside the Psychedelic Underground - RollingStone.com [Last Updated On: March 9th, 2017] [Originally Added On: March 9th, 2017]
- What Psychedelics Really Do to Your Brain - Rolling Stone - RollingStone.com [Last Updated On: March 10th, 2017] [Originally Added On: March 10th, 2017]
- Hallucinogens Help, According to a Mom's Memoir and Son's Documentary - Bedford + Bowery [Last Updated On: April 8th, 2017] [Originally Added On: April 8th, 2017]
- Meditation and the psychedelic drug ayahuasca seem to change the brain in surprisingly similar ways - Businessinsider India [Last Updated On: April 8th, 2017] [Originally Added On: April 8th, 2017]
- Tripping out: the highs and lows of psychedelic therapy - Marie Claire UK [Last Updated On: April 8th, 2017] [Originally Added On: April 8th, 2017]
- Stop Policing Psychedelic Science - Motherboard [Last Updated On: June 6th, 2017] [Originally Added On: June 6th, 2017]
- America's Trippiest Chemist: Making Psychedelics 'Was Fun' - Motherboard [Last Updated On: June 6th, 2017] [Originally Added On: June 6th, 2017]
- The Three Types of Hallucinogens: Psychedelics ... [Last Updated On: June 7th, 2017] [Originally Added On: June 7th, 2017]
- Cary Grant was one of the first to benefit from LSD therapy - Quartz [Last Updated On: June 11th, 2017] [Originally Added On: June 11th, 2017]
- What it's like to take psychedelics in small doses at breakfast - New Scientist [Last Updated On: June 14th, 2017] [Originally Added On: June 14th, 2017]
- 'Changing Our Minds' explores psychedelic drugs and spiritual healing - Religion News Service [Last Updated On: June 14th, 2017] [Originally Added On: June 14th, 2017]
- Q&A With Psychedelic Stand-Up and LaughFest Headliner Shane Mauss - Flagpole Magazine [Last Updated On: June 20th, 2017] [Originally Added On: June 20th, 2017]
- Q&A: LaughFest comedian talks science and psychedelics - Red and Black [Last Updated On: June 20th, 2017] [Originally Added On: June 20th, 2017]
- 'Changing Our Minds' explores psychedelic drugs and spiritual healing - The Daily Tribune [Last Updated On: June 21st, 2017] [Originally Added On: June 21st, 2017]
- Shane Mauss brings Good Trip Comedy Tour to town - Chattanooga Times Free Press [Last Updated On: June 22nd, 2017] [Originally Added On: June 22nd, 2017]
- 'Changing Our Minds' explores psychedelic drugs and spiritual healing - The Oakland Press [Last Updated On: June 22nd, 2017] [Originally Added On: June 22nd, 2017]
- Director Ana Lily Amirpour on Cannibalism, Psychedelics, and 'Horrifying' Racism Allegations - Jezebel [Last Updated On: June 23rd, 2017] [Originally Added On: June 23rd, 2017]
- Majority of Americans ready to embrace psychedelic therapy - YouGov US [Last Updated On: June 24th, 2017] [Originally Added On: June 24th, 2017]
- The Refugee Funding America's Psychedelic Renaissance - VICE [Last Updated On: June 24th, 2017] [Originally Added On: June 24th, 2017]
- Open Your Mind This Weekend at Europe's Largest Psychedelic Conference - VolteFace Magazine (blog) [Last Updated On: June 27th, 2017] [Originally Added On: June 27th, 2017]
- Psychedelics and Virtual Reality Make a Trendy but Illegal Therapy - Inverse [Last Updated On: June 27th, 2017] [Originally Added On: June 27th, 2017]
- The war on drugs is back. Will psychedelic drug research survive? - The Verge [Last Updated On: June 29th, 2017] [Originally Added On: June 29th, 2017]
- Tune in, Turn on, Stay in School - Study Breaks [Last Updated On: July 2nd, 2017] [Originally Added On: July 2nd, 2017]
- Cannabist Show: He's psychedelic comedian Shane Mauss - The Cannabist [Last Updated On: July 2nd, 2017] [Originally Added On: July 2nd, 2017]
- The brain on DMT: mapping the psychedelic drug's effects - Wired.co.uk [Last Updated On: July 3rd, 2017] [Originally Added On: July 3rd, 2017]
- Psychedelics Could Help Asia's Mental Health Care, But Stigma Remains Roadblock - TheFix.com [Last Updated On: July 3rd, 2017] [Originally Added On: July 3rd, 2017]
- Is LSD the new coffee? - FactorDaily [Last Updated On: July 4th, 2017] [Originally Added On: July 4th, 2017]
- My grandfather was a death row doctor. He tested psychedelic drugs on Texas inmates. - Texas Tribune [Last Updated On: July 5th, 2017] [Originally Added On: July 5th, 2017]
- About Us | Trusted News Source for Psychedelic Research ... [Last Updated On: July 6th, 2017] [Originally Added On: July 6th, 2017]
- Do Psychedelic Drugs Cause the 'Prophetic Effect'? - Breaking Israel News [Last Updated On: July 11th, 2017] [Originally Added On: July 11th, 2017]
- Are psychedelics the new medical marijuana? - WTSP 10 News [Last Updated On: July 14th, 2017] [Originally Added On: July 14th, 2017]
- Psychiatrists Say Cannabis Medicine Has Psychedelic Properties - The Marijuana Times [Last Updated On: July 15th, 2017] [Originally Added On: July 15th, 2017]
- Can Psychedelics Be Therapy? Allow Research to Find Out - New York Times [Last Updated On: July 17th, 2017] [Originally Added On: July 17th, 2017]
- Countdown To (Legalized) Ecstasy! Rick Doblin, MAPS, & the Psychedelic Renaissance [Podcast] - Reason (blog) [Last Updated On: July 20th, 2017] [Originally Added On: July 20th, 2017]
- Should We Reclassify Marijuana as a Hallucinogen? - Big Think [Last Updated On: July 20th, 2017] [Originally Added On: July 20th, 2017]
- Do You Take Drugs at Festivals? This Initiative is Working on Keeping You Safe - PoliticalCritique.org [Last Updated On: July 20th, 2017] [Originally Added On: July 20th, 2017]
- Psychedelic drugs could tackle depression in a way that antidepressants can't - INSIDER [Last Updated On: July 22nd, 2017] [Originally Added On: July 22nd, 2017]
- Psychedelic Shine takes a trip to the skies in Boulder - Boulder Daily Camera [Last Updated On: July 22nd, 2017] [Originally Added On: July 22nd, 2017]
- Reasons to Consider Trying Psychedelics - FoxWeekly [Last Updated On: July 27th, 2017] [Originally Added On: July 27th, 2017]
- Psychedelics and Normality - HuffPost [Last Updated On: July 27th, 2017] [Originally Added On: July 27th, 2017]
- New book about psychedelics and weird human experiences - Boing Boing [Last Updated On: July 27th, 2017] [Originally Added On: July 27th, 2017]
- Scientists Want You to Give Them Money to Study ... [Last Updated On: July 29th, 2017] [Originally Added On: July 29th, 2017]
- What Has Awe Done for Me Lately? - HuffPost [Last Updated On: August 1st, 2017] [Originally Added On: August 1st, 2017]
- For children, it's beyond psychedelics - The Hans India - The Hans India [Last Updated On: August 1st, 2017] [Originally Added On: August 1st, 2017]
- Expanding consciousness - 48 Hills [Last Updated On: August 2nd, 2017] [Originally Added On: August 2nd, 2017]
- THE FUTURE OF PSYCHEDELICS: Are LSD and Mushrooms The New Prozac? - Dope Magazine [Last Updated On: August 5th, 2017] [Originally Added On: August 5th, 2017]
- Psychedelic drugs saved my life. So why aren't they prescribed? - Wired.co.uk [Last Updated On: August 9th, 2017] [Originally Added On: August 9th, 2017]
- LSD as therapy: How scientists are reclaiming psychedelics ... [Last Updated On: August 9th, 2017] [Originally Added On: August 9th, 2017]
- The foundation of Western philosophy is probably rooted in psychedelics - Quartz [Last Updated On: August 12th, 2017] [Originally Added On: August 12th, 2017]
- Crazy Enough to be Correct - HuffPost [Last Updated On: August 15th, 2017] [Originally Added On: August 15th, 2017]